PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
网页Optimizing Patient Recruitment & Retention in Influenza Studies. Aug 16, 2024 Webinars. With the flu season rapidly approaching, there is a surge in influenza and vaccine-related studies. These studies often face the significant challenge of a very short recruitment window, which necessitates thorough preparation and strategic planning during ...
Moderna shares positive late-stage results for COVID-19/flu …
网页2024年6月11日 · Moderna has shared positive late-stage results for its investigational combination vaccine against influenza and COVID-19. The ongoing phase 3 trial has been evaluating the candidate, mRNA-1083, in two age-group cohorts of …
Sales - PMLiVE
网页Eli Lilly and Genetic Leap partner to develop RNA-targeted therapies in deal worth $409m. Sep 10, 2024 | News, Sales. The companies will use Genetic Leap’s AI platform to generate oligonucleotide drugs against targets selected by Lilly. Read More.
Regulatory - PMLiVE
网页Novartis’ Fabhalta recommended by NICE to treat rare blood disorder PNH. Sep 4, 2024 News Regulatory. Paroxysmal nocturnal haemoglobinuria affects approximately ten to 20 people per million worldwide. Read More.
PME - Home
网页How AI and digital innovations can help agencies and pharma support HCPs in the fight against COVID-19 - PME Supplement August 2020. As the realities of COVID-19 hit and lockdown restrictions came into force around the world, agencies and pharma suddenly found themselves embracing AI and digital innovations at an accelerated rate.
Pfizer’s Paxlovid receives positive opinion from CHMP - PMLiVE
网页2022年1月28日 · If authorised, the drug would be the first COVID-19 oral treatment recommended in the EU
Moderna and GSK advance coronavirus vaccine candidates
网页2020年2月25日 · Developments come amid rapidly growing cases across the globe. Moderna and GlaxoSmithKline are leading the race to develop a vaccine for the novel coronavirus, with both companies advancing candidates forward. Biotech company Moderna announced yesterday that its has released the first batch of its vaccine – mRNA-1273 – …
Intelligence - PMLiVE
网页Intelligence. Optimizing Patient Recruitment & Retention in Influenza Studies. With the flu season rapidly approaching, there is a surge in influenza and vaccine-related studies. These studies often face the significant challenge of a very short recruitment window, which necessitates thorough preparation and strategic planning during the design ...
Johnson & Johnson's IL-23 inhibitor Tremfya granted FDA …
网页2024年9月12日 · Johnson & Johnson’s (J&J) dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with moderately to severely active ulcerative colitis (UC). Estimated to affect more than one million people in the US, UC is a type of inflammatory bowel disease (IBD) that …
US demand for COVID-19 antibody treatments rising fast
网页2021年8月31日 · With the US summer surge of COVID-19 seeing 100,000 hospitalisations per day, Regeneron and GSK/Vir report rising demand for their antibody treatments. Regeneron’s antibody cocktail of casirivimab and imdevimab, known as REGEN-COV in the US, and GSK/Vir’s sotrovimab have been shown to prevent and treat acute COVID-19 …